

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims.

1. (Original) An isolated antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:
 - (a) a protein consisting of amino acid residues -46 to 373 of SEQ ID NO:2;
 - (b) a protein consisting of amino acid residues -23 to 373 of SEQ ID NO:2;
 - (c) a protein consisting of amino acid residues 1 to 373 of SEQ ID NO:2;
 - (d) a protein consisting of amino acid residues 24 to 373 of SEQ ID NO:2;
 - (e) a protein consisting of amino acid residues 85 to 165 of SEQ ID NO:2;
 - (f) a protein consisting of amino acid residues 108 to 121 of SEQ ID NO:2;
 - (g) a protein consisting of a fragment of SEQ ID NO:2, wherein said fragment comprises at least 30 contiguous amino acid residues of SEQ ID NO:2; and
 - (h) a protein consisting of a fragment of SEQ ID NO:2, wherein said fragment comprises at least 50 contiguous amino acid residues of SEQ ID NO:2.
2. (Original) The antibody or fragment thereof of claim 1 that specifically binds protein (a).
3. (Original) The antibody or fragment thereof of claim 1 that specifically binds protein (b).
4. (Original) The antibody or fragment thereof of claim 1 that specifically binds protein (c).
5. (Original) The antibody or fragment thereof of claim 1 that specifically binds protein (d).
6. (Original) The antibody or fragment thereof of claim 1 that specifically binds protein (e).
7. (Original) The antibody or fragment thereof of claim 1 that specifically binds protein (f).
8. (Original) The antibody or fragment thereof of claim 1 that specifically binds protein (g).
9. (Original) The antibody or fragment thereof of claim 1 that specifically binds protein (h).

10. (Original) The antibody or fragment thereof of claim 2 that specifically binds protein (b).
11. (Original) The antibody or fragment thereof of claim 6 wherein said protein bound by said antibody or fragment thereof is glycosylated.
12. (Original) The antibody or fragment thereof of claim 6 which is a polyclonal antibody.
13. (Original) The antibody or fragment thereof of claim 6 which is selected from the group consisting of:
 - (a) a chimeric antibody;
 - (b) a single chain antibody; and
 - (c) a Fab fragment.
14. (Original) The antibody or fragment thereof of claim 6 which is labeled.
15. (Previously Presented) The antibody or fragment thereof of claim 14 wherein the label is selected from the group consisting of:
 - (a) an enzyme; and
 - (b) a fluorescent label.
16. (Original) The antibody or fragment thereof of claim 6 wherein said antibody specifically binds to said protein in a Western blot.
17. (Original) The antibody or fragment thereof of claim 6 wherein said antibody specifically binds to said protein in an ELISA.
18. (Original) An isolated cell that produces the antibody or fragment thereof of claim 6.
19. (Original) A hybridoma that produces the antibody or fragment thereof of claim 6.

20. (Previously Presented) A method of detecting VEGF-2 protein in a biological sample comprising:

- (a) contacting the biological sample with the antibody or fragment thereof of claim 6; and
- (b) detecting the VEGF-2 protein in the biological sample.

21. (Original) The method of claim 20 wherein the antibody or fragment thereof is a polyclonal antibody.

22. (Original) An isolated antibody or fragment thereof obtained from an animal that has been immunized with a protein selected from the group consisting of:

- (a) a protein comprising the amino acid sequence of amino acid residues -46 to 373 of SEQ ID NO:2;
- (b) a protein comprising the amino acid sequence of amino acid residues -23 to 373 of SEQ ID NO:2;
- (c) a protein comprising the amino acid sequence of amino acid residues 1 to 373 of SEQ ID NO:2;
- (d) a protein comprising the amino acid sequence of amino acid residues 24 to 373 of SEQ ID NO:2;
- (e) a protein comprising the amino acid sequence of amino acid residues 85 to 165 of SEQ ID NO:2;
- (f) a protein comprising the amino acid sequence of amino acid residues 108 to 121 of SEQ ID NO:2;
- (g) a protein comprising the amino acid sequence of at least 30 contiguous amino acid residues of SEQ ID NO:2; and
- (h) a protein comprising the amino acid sequence of at least 50 contiguous amino acid residues of SEQ ID NO:2;

wherein said antibody or fragment thereof specifically binds to said amino acid sequence.

23. (Original) The antibody or fragment thereof of claim 22 obtained from an animal immunized with protein (a).
24. (Original) The antibody or fragment thereof of claim 22 obtained from an animal immunized with protein (b).
25. (Original) The antibody or fragment thereof of claim 22 obtained from an animal immunized with protein (c).
26. (Original) The antibody or fragment thereof of claim 22 obtained from an animal immunized with protein (d).
27. (Original) The antibody or fragment thereof of claim 22 obtained from an animal immunized with protein (e).
28. (Original) The antibody or fragment thereof of claim 22 obtained from an animal immunized with protein (f).
29. (Original) The antibody or fragment thereof of claim 22 obtained from an animal immunized with protein (g).
30. (Original) The antibody or fragment thereof of claim 22 obtained from an animal immunized with protein (h).
31. (Original) The antibody or fragment thereof of claim 22 which is a monoclonal antibody.
32. (Original) The antibody or fragment thereof of claim 22 which is selected from the group consisting of:
 - (a) a chimeric antibody;
 - (b) a polyclonal antibody;
 - (c) a single chain antibody; and

(d) a Fab fragment.

33. (Original) An isolated monoclonal antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:

- (a) a protein consisting of amino acid residues -46 to 373 of SEQ ID NO:2;
- (b) a protein consisting of amino acid residues -23 to 373 of SEQ ID NO:2;
- (c) a protein consisting of amino acid residues 1 to 373 of SEQ ID NO:2;
- (d) a protein consisting of amino acid residues 24 to 373 of SEQ ID NO:2;
- (e) a protein consisting of amino acid residues 85 to 165 of SEQ ID NO:2;
- (f) a protein consisting of amino acid residues 108 to 121 of SEQ ID NO:2;
- (g) a protein consisting of a fragment of SEQ ID NO:2, wherein said fragment comprises at least 30 contiguous amino acid residues of SEQ ID NO:2; and
- (h) a protein consisting of a fragment of SEQ ID NO:2, wherein said fragment comprises at least 50 contiguous amino acid residues of SEQ ID NO:2.

34. (Original) The antibody or fragment thereof of claim 33 that specifically binds protein (a).

35. (Original) The antibody or fragment thereof of claim 33 that specifically binds protein (b).

36. (Original) The antibody or fragment thereof of claim 33 that specifically binds protein (c).

37. (Original) The antibody or fragment thereof of claim 33 that specifically binds protein (d).

38. (Original) The antibody or fragment thereof of claim 33 that specifically binds protein (e).

39. (Original) The antibody or fragment thereof of claim 33 that specifically binds protein (f).

40. (Original) The antibody or fragment thereof of claim 33 that specifically binds protein (g).

41. (Original) The antibody or fragment thereof of claim 33 that specifically binds protein (h).

42. (Previously Presented) The antibody or fragment thereof of claim 34 that specifically binds protein (b).
43. (Original) The antibody or fragment thereof of claim 38 wherein said protein bound by said antibody or fragment thereof is glycosylated.
44. (Original) The antibody or fragment thereof of claim 38 which is selected from the group consisting of:
- (a) a chimeric antibody;
 - (b) a single chain antibody; and
 - (c) a Fab fragment.
45. (Original) The antibody or fragment thereof of claim 38 which is labeled.
46. (Previously Presented) The antibody of claim 45 wherein the label is selected from the group consisting of:
- (a) an enzyme; and
 - (b) a fluorescent label.
47. (Original) The antibody or fragment thereof of claim 38 wherein said antibody specifically binds to said protein in a Western blot.
48. (Original) The antibody or fragment thereof of claim 38 wherein said antibody specifically binds to said protein in an ELISA.
49. (Original) An isolated cell that produces the antibody or fragment thereof of claim 38.
50. (Original) A hybridoma that produces the antibody or fragment thereof of claim 38.
51. (Previously Presented) A method of detecting VEGF-2 protein in a biological sample comprising:

- (a) contacting the biological sample with the antibody or fragment thereof of claim 38; and
 - (b) detecting the VEGF-2 protein in the biological sample.
52. (Original) An isolated antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:
- (a) a protein consisting of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 97149;
 - (b) a protein consisting of the mature form of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97149;
 - (c) a protein consisting of a fragment of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97149, wherein said fragment comprises at least 30 contiguous amino acid residues of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97149; and
 - (d) a protein consisting of a fragment of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97149, wherein said fragment comprises at least 50 contiguous amino acid residues of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97149.
53. (Original) The antibody or fragment thereof of claim 52 that specifically binds protein (a).
54. (Original) The antibody or fragment thereof of claim 52 that specifically binds protein (b).
55. (Original) The antibody or fragment thereof of claim 52 that specifically binds protein (c).
56. (Original) The antibody or fragment thereof of claim 52 that specifically binds protein (d).
57. (Original) The antibody or fragment thereof of claim 53 that specifically binds protein (b).
58. (Original) The antibody or fragment thereof of claim 54 wherein said protein bound by said antibody or fragment thereof is glycosylated.

59. (Original) The antibody or fragment thereof of claim 54 which is a polyclonal antibody.
60. (Original) The antibody or fragment thereof of claim 54 which is selected from the group consisting of:
- (a) a chimeric antibody;
 - (b) a single chain antibody; and
 - (c) a Fab fragment.
61. (Original) The antibody or fragment thereof of claim 54 which is labeled.
62. (Previously Presented) The antibody of claim 61 wherein the label is selected from the group consisting of:
- (a) an enzyme; and
 - (b) a fluorescent label.
63. (Original) The antibody or fragment thereof of claim 54 wherein said antibody specifically binds to said protein in a Western blot.
64. (Original) The antibody or fragment thereof of claim 54 wherein said antibody specifically binds to said protein in an ELISA.
65. (Original) An isolated cell that produces the antibody or fragment thereof of claim 54.
66. (Original) A hybridoma that produces the antibody or fragment thereof of claim 54.
67. (Previously Presented) A method of detecting VEGF-2 protein in a biological sample comprising:
- (a) contacting the biological sample with the antibody or fragment thereof of claim 54; and
 - (b) detecting the VEGF-2 protein in the biological sample.

68. (Original) The method of claim 67 wherein the antibody or fragment thereof is a polyclonal antibody.

69. (Original) An isolated antibody or fragment thereof obtained from an animal that has been immunized with a protein selected from the group consisting of:

- (a) a protein comprising the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 97149;
- (b) a protein comprising the amino acid sequence of the mature form of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97149;
- (c) a protein comprising the amino acid sequence of at least 30 contiguous amino acid residues of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97149; and
- (d) a protein comprising the amino acid sequence of at least 50 contiguous amino acid residues the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97149;

wherein said antibody or fragment thereof specifically binds to said amino acid sequence.

70. (Original) The antibody or fragment thereof of claim 69 obtained from an animal immunized with protein (a).

71. (Original) The antibody or fragment thereof of claim 69 obtained from an animal immunized with protein (b).

72. (Original) The antibody or fragment thereof of claim 69 obtained from an animal immunized with protein (c).

73. (Original) The antibody or fragment thereof of claim 69 obtained from an animal immunized with protein (d).

74. (Original) The antibody or fragment thereof of claim 69 which is a monoclonal antibody.
75. (Original) The antibody or fragment thereof of claim 69 which is selected from the group consisting of:
- (a) a chimeric antibody;
 - (b) a polyclonal antibody;
 - (c) a single chain antibody; and
 - (d) a Fab fragment.
76. (Original) An isolated monoclonal antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:
- (a) a protein consisting of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 97149;
 - (b) a protein consisting of the mature form of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97149;
 - (c) a protein consisting of a fragment of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97149, wherein said fragment comprises at least 30 contiguous amino acid residues of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97149; and
 - (d) a protein consisting of a fragment of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97149, wherein said fragment comprises at least 50 contiguous amino acid residues of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97149.
77. (Original) The antibody or fragment thereof of claim 76 that specifically binds protein (a).
78. (Original) The antibody or fragment thereof of claim 76 that specifically binds protein (b).
79. (Original) The antibody or fragment thereof of claim 76 that specifically binds protein (c).
80. (Original) The antibody or fragment thereof of claim 76 that specifically binds protein (d).

81. (Original) The antibody or fragment thereof of claim 77 that specifically binds protein (b).
82. (Original) The antibody or fragment thereof of claim 78 wherein said protein bound by said antibody or fragment thereof is glycosylated.
83. (Original) The antibody or fragment thereof of claim 78 which is selected from the group consisting of:
 - (a) a chimeric antibody;
 - (b) a single chain antibody; and
 - (c) a Fab fragment.
84. (Original) The antibody or fragment thereof of claim 78 which is labeled.
85. (Previously Presented) The antibody of claim 84 wherein the label is selected from the group consisting of:
 - (a) an enzyme; and
 - (b) a fluorescent label.
86. (Original) The antibody or fragment thereof of claim 78 wherein said antibody specifically binds to said protein in a Western blot.
87. (Original) The antibody or fragment thereof of claim 78 wherein said antibody specifically binds to said protein in an ELISA.
88. (Original) An isolated cell that produces the antibody or fragment thereof of claim 78.
89. (Original) A hybridoma that produces the antibody or fragment thereof of claim 78.
90. (Previously Presented) A method of detecting VEGF-2 protein in a biological sample comprising:

- (a) contacting the biological sample with the antibody or fragment thereof of claim 78; and
- (b) detecting the VEGF-2 protein in the biological sample.

- 91. (Original) A method of inhibiting angiogenesis in a patient comprising administering to the patient the antibody of any one of claims 1, 6, 22, 33, 38, 52, 54, 69, 76, or 78.
- 92. (Original) A method of inhibiting neovascularization in a patient comprising administering to the patient the antibody of claim 1, 6, 22, 33, 38, 52, 54, 69, 76, or 78.
- 93. (Original) A method of inhibiting a tumor in a patient comprising administering to the patient the antibody of claim 1, 6, 22, 33, 38, 52, 54, 69, 76, or 78.
- 94. (Original) A method of inhibiting diabetic retinopathy in a patient comprising administering to the patient the antibody of claim 1, 6, 22, 33, 38, 52, 54, 69, 76, or 78.
- 95. (Original) A method of inhibiting psoriasis in a patient comprising administering to the patient the antibody of claim 1, 6, 22, 33, 38, 52, 54, 69, 76, or 78.
- 96. (Original) A method of inhibiting rheumatoid arthritis in a patient comprising administering to the patient the antibody of claim 1, 6, 22, 33, 38, 52, 54, 69, 76, or 78.
- 97. (Previously Presented) An antibody which binds to a protein consisting of the mature form of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 97149.
- 98. (Previously Presented) A composition comprising an antibody according to claim 97, in a pharmaceutically acceptable carrier.
- 99. (Previously Presented) An antibody according to claim 97 that is a monoclonal antibody.

100. (Previously Presented) A composition comprising an antibody according to claim 99, in a pharmaceutically acceptable carrier.

101. (Previously Presented) An antibody according to claim 99, further comprising a label.

102. (Previously Presented) An antibody according to claim 97, further comprising a label.

103. (Previously Presented) An antibody which binds to a protein produced by a method comprising:

- (a) expressing a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 from a mammalian host cell; and
- (b) recovering the protein.

104. (Previously Presented) The antibody of claim 103, wherein the mammalian host cell comprises a CHO host cell.

105. (Previously Presented) The antibody of claim 103, wherein the mammalian host cell comprises a COS host cell.

106. (Previously Presented) A composition comprising an antibody according to claim 103, in a pharmaceutically acceptable carrier.

107. (Previously Presented) An antibody according to claim 103 that is a monoclonal antibody.

108. (Previously Presented) A composition comprising an antibody according to claim 107, in a pharmaceutically acceptable carrier.

109. (Previously Presented) An antibody according to claim 107, further comprising a label.

110. (Previously Presented) An antibody according to claim 103, further comprising a label.